Sustainability | April 17, 2025
Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
Strengthening capabilities in Peptide Therapeutics and CDMO services
Raichur site is the group’s largest API facility and part of a wider network of seven sites
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Subscribe To Our Newsletter & Stay Updated
